ZYUS Life Sciences Corporation ZYUS
TSXV · Canada · Health Technology
CAD 0.5800-0.02 (-3.33%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ZYUS Life Sciences Corporation (the "Company" and or "ZYUS") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced positive topline results from its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial evaluating dosing, safety, and efficacy of Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe canc
ZYUS Life Sciences Corporation (the "ZYUS" and or "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel drug product candidates for chronic pain is pleased to announce that it anticipates announcing topline results from its Phase 2a UTOPIA-1 clinical trial on September 30, 2026. In addition, the Company is pleased to announce the results of its Annual General and Special Meeting of Shareholders (the "Meeting") held on September
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.